Prostate Cancer Combination Therapy Boom Still Holds Value — For Now

Treatment of metastatic hormone-sensitive prostate cancer has shifted toward combination therapies. The prostate cancer treatment market is projected to grow from $13.5 billion in 2025 to $29.9 billion in 2034, at a compound annual growth rate of 9.2%. From an investment perspective, attention is focused on the discrepancy between the real-world efficacy of combination therapies and stock valuations.

Wide Disparity in P/E Ratios Among Stocks of the Four Pharmaceutical Companies with the Deepest Footprint in Combination Therapy for Prostate Cancer:Johnson & JohnsonApproximately 26 times; the actual sales growth of the oncology business in 2025 was 20.9%;AstraZenecaNearly 28 times, with full-year 2025 revenue of $58.7 billion;PfizerTrailing P/E ratio of approximately 20x; full-year 2025 revenue declined 2% to $62.6 billion; Bristol Myers SquibbBristol-Myers SquibbApproximately 16 times, with 2025 revenue reaching approximately USD 52 billion.

Bristol-Myers Squibb Faces Severe Structural Headwinds; Analysts Project $10–13 Billion in Revenue at Risk by 2028 Due to Patent Expirations, with Market Forecasts Indicating Declines in Revenue and Earnings. However, a P/E Ratio of 16x May Overstate the Impact of the Revenue Decline.

Johnson & Johnson’s 26x and AstraZeneca’s 28x price-to-earnings ratios indicate high market expectations for growth in their oncology businesses, but limited future growth potential after buying in at such high valuations.

For retirement portfolios, investment decisions hinge on buying capacity. If growth at Johnson & Johnson and AstraZeneca slows, or if Bristol-Myers Squibb’s new drug portfolio expands rapidly, the valuation gap will narrow; conversely, if the impact of patent cliffs is more severe, the gap will widen. The key lies in whether Johnson & Johnson and AstraZeneca can sustain growth in their oncology businesses, and whether Bristol-Myers Squibb and Pfizer can leverage their R&D pipelines to halt revenue declines.

Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large language model based on publicly available information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making. For authoritative information, please refer to the actual official announcements. If you have any questions, please contact: biz@staff.sina.com.cn.

Managing Editor: Xiaolang Express